Anticoagulation Changes Following Major and Clinically Relevant Nonmajor Bleeding Events in Non-valvular Atrial Fibrillation Patients

医学 心房颤动 心脏病学 大出血 内科学 拜瑞妥 华法林
作者
Thane Feldeisen,Constantina Alexandris-Souphis,Brian Haymart,Xiaowen Kong,Eva M Kline-Rogers,Faheem Handoo,Scott Kaatz,Mona A. Ali,J Kozłowski,Vinay I. Shah,Gregory D Krol,James B. Froehlich,Geoffrey D. Barnes
出处
期刊:Journal of Pharmacy Practice [SAGE Publishing]
卷期号:36 (3): 542-547 被引量:5
标识
DOI:10.1177/08971900211064189
摘要

Background: Bleeding events are common complications of oral anticoagulant drugs, including both warfarin and the direct oral anticoagulants (DOACs). Some patients have their anticoagulant changed or discontinued after experiencing a bleeding event, while others continue the same treatment. Differences in anticoagulation management between warfarin- and DOAC-treated patients following a bleeding event are unknown. Methods: Patients with non-valvular atrial fibrillation from six anticoagulation clinics taking warfarin or DOAC therapy who experienced an International Society of Thrombosis and Haemostasis (ISTH)-defined major or clinically relevant non-major (CRNM) bleeding event were identified between 2016 and 2020. The primary outcome was management of the anticoagulant following bleeding (discontinuation, change in drug class, and restarting of same drug class). DOAC- and warfarin-treated patients were propensity matched based on the individual elements of the CHA2DS2-VASc and HAS-BLED scores as well as the severity of the bleeding event. Results: Of the 509 patients on warfarin therapy and 246 on DOAC therapy who experienced a major or CRNM bleeding event, the majority of patients continued anticoagulation therapy. The majority of warfarin (231, 62.6%) and DOAC patients (201, 81.7%) restarted their previous anticoagulation. Conclusion: Following a bleeding event, most patients restarted anticoagulation therapy, most often with the same type of anticoagulant that they previously had been taking.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
bkagyin的应助被徐徐采纳,获得10
刚刚
lifeng完成签到 ,获得积分10
刚刚
lico发布了新的文献求助10
刚刚
刚刚
1秒前
广发牛勿完成签到,获得积分10
1秒前
WANGZIHAN完成签到 ,获得积分20
1秒前
谨慎玫瑰完成签到,获得积分10
1秒前
樊yt发布了新的文献求助10
1秒前
Wxiny驳回了fantasy的应助
1秒前
LYY完成签到,获得积分10
2秒前
六六发布了新的文献求助10
2秒前
2秒前
2秒前
lierre完成签到,获得积分10
2秒前
思源的应助被zhao采纳,获得10
3秒前
3秒前
dongshao2027的应助被秀丽的夜南采纳,获得50
3秒前
caigou发布了新的文献求助10
3秒前
熊猫海发布了新的文献求助20
4秒前
4秒前
4秒前
4秒前
烟花的应助被杜冷丁采纳,获得10
4秒前
4秒前
jun完成签到,获得积分10
4秒前
4秒前
m7m发布了新的文献求助40
5秒前
5秒前
Present发布了新的文献求助10
5秒前
蟹老板完成签到,获得积分10
5秒前
风趣靳发布了新的文献求助10
5秒前
6秒前
科目三的应助被青黛采纳,获得10
6秒前
汉堡包的应助被江西卷背刺我采纳,获得10
6秒前
希望天下0贩的0的应助被zhenpeng采纳,获得10
6秒前
7秒前
7秒前
搜集达人的应助被sanshu采纳,获得10
8秒前
Humingyu的应助被黄健丰采纳,获得10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8182513
求助须知:如何正确求助?哪些是违规求助? 9571996
关于积分的说明 21821383
捐赠科研通 7778989
什么是DOI,文献DOI怎么找? 3433670
关于科研通互助平台的介绍 2557827
邀请新用户注册赠送积分活动 2479731